BiotechMashup

A new study showed no difference in nonsuicide mortality between people taking ziprasidone and another second-generation anti-psychotic in real-world use.

(European Society for Medical Oncology) The anti-inflammatory drug celecoxib may be a useful additional treatment for people with breast cancer, Dutch researchers report at the IMPAKT Breast Cancer Conference in Brussels.

(University of Pennsylvania School of Medicine) A study published online this month in the American Journal of Psychiatry in advance of print publication in February 2011 showed no difference in nonsuicide mortality between people taking ziprasidone and another second-generation anti-psychotic in real-world use.

A nondisease-causing virus kills human breast cancer cells in the laboratory, creating opportunities for potential new cancer therapies, according to researchers who tested the virus on three different breast cancer types that represent the multiple stages of breast cancer development.

The anti-inflammatory drug celecoxib may be a useful additional treatment for people with breast cancer, Dutch researchers report.

Researchers have discovered how some recently approved drugs act against cancer cells. The finding may lead to a more effectively targeted anti-cancer strategy.

Breast cancer stem cells, the aggressive cells thought to be resistant to current anti-cancer therapies and which promote metastasis, are stimulated by estrogen via a pathway that mirrors normal stem cell development. Disrupting the pathway, researchers were able to halt the expansion of breast CSCs, a finding that suggests a new drug therapy target. The study was done in mice.

(DOE/Pacific Northwest National Laboratory) Packaging anti-cancer drugs into particles of chemically modified silica improve the drugs' ability to fight skin cancer in mice, according to new research. Results published May 3 in the Journal of the American Chemical Society online show the honeycombed particles can help anti-cancer antibodies prevent tumor growth and prolong the lives of mice.

(Tufts University, Health Sciences) Breast cancer stem cells, the aggressive cells thought to be resistant to current anti-cancer therapies and which promote metastasis, are stimulated by estrogen via a pathway that mirrors normal stem cell development. Disrupting the pathway, researchers were able to halt the expansion of breast CSCs, a finding that suggests a new drug therapy target. The study, done in mice, is published in the Proceedings of the National Academy of Sciences early edition.